Previous 10 | Next 10 |
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareh...
2023-04-25 14:10:29 ET Gainers: Simpson Manufacturing ( SSD ) +11% . Loop Industries ( LOOP ) +10% . Losers: Ecopetrol ( EC ) -15% . Mesabi Trust ( MSB ) -15% . CBL International ( BANL ) -13% . National Energy Services Reunited ( NESR...
2023-04-14 16:26:29 ET Mesabi Trust ( NYSE: MSB ) said Friday its board will not declare distribution in April, compared to the distribution of $1.04 per unit for the same period last year. MSB said the decision to declare no distribution reflects its caution about...
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and ...
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the...
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022. Dr. Silviu Itescu, Chief Execut...
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the ...
Gainers: Kosmos Energy ( KOS ) +12% . McEwen Mining ( MUX ) +12% . Glatfelter ( GLT ) +11% . SenesTech ( SNES ) +11% . Tsakos Energy Navigation ( TNP ) +9% . Losers: Atlas Lithium ( ATLX ) -17% . Mesabi Trust ( MSB ) -10% . Range R...
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2022. The web...
Summary This is the first 2023 update on the long-term value portfolios consistently beating the S&P 500 since inception with S&P 500 +3.40%, DJIA -2.0% YTD. For 2023 the Piotroski-Graham value portfolio is up 15.0%, Negative Forensic Portfolio is up 11.5%, and Positive Fo...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...
2024-07-13 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....